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ABSTRACT: The Baeyer−Villiger monooxygenases
(BVMOs) are a family of bacterial ﬂavoproteins that catalyze
the synthetically useful Baeyer−Villiger oxidation reaction.
This involves the conversion of ketones into esters or cyclic
ketones into lactones by introducing an oxygen atom adjacent
to the carbonyl group. The BVMOs oﬀer exquisite regio- and
enantiospeciﬁcity while acting on a wide range of substrates.
They use only NADPH and oxygen as cosubstrates, and
produce only NADP+ and water as byproducts, making them
environmentally attractive for industrial purposes. Here, we
report the ﬁrst crystal structure of a BVMO, cyclohexanone monooxygenase (CHMO) from Rhodococcus sp. HI-31 in complex
with its substrate, cyclohexanone, as well as NADP+ and FAD, to 2.4 Å resolution. This structure shows a drastic rotation of the
NADP+ cofactor in comparison to previously reported NADP+-bound structures, as the nicotinamide moiety is no longer
positioned above the ﬂavin ring. Instead, the substrate, cyclohexanone, is found at this location, in an appropriate position for the
formation of the Criegee intermediate. The rotation of NADP+ permits the substrate to gain access to the reactive ﬂavin
peroxyanion intermediate while preventing it from diﬀusing out of the active site. The structure thus reveals the conformation of
the enzyme during the key catalytic step. CHMO is proposed to undergo a series of conformational changes to gradually move
the substrate from the solvent, via binding in a solvent excluded pocket that dictates the enzyme’s chemospeciﬁcity, to a location
above the ﬂavin−peroxide adduct where catalysis occurs.
■ INTRODUCTION
The century-old Baeyer−Villiger (BV) reaction is the oxidative
cleavage of a carbon−carbon bond adjacent to a carbonyl; this
process transforms ketones to esters and cyclic ketones to
lactones using peracids.
1,2 While this reaction has proven to be
very useful to synthetic chemists, it has a number of
shortcomings that include the use of costly and hazardous
reagents or chlorinated solvents while producing more waste
than product for lack of functional group selectivity and
enantioselectivity. Although metal-catalyzed enantioselective
BV reactions have also been developed, both cost and
contamination of the products with metals may present a
serious problem.
3 For a variety of reasons, Baeyer−Villiger
monooxygenases (BVMOs), a family of bacterial ﬂavoproteins
that catalyze the BV reaction,
4−9 have garnered much attention.
Most BVMOs are involved in the second step of
biodegradation of C5 to C15 alicyclic alcohols such as
cyclopentanol, cyclohexanol, and cyclopentadecanol, providing
a carbon source for the organisms via the formation of Krebs
cycle intermediates.
6,10,11 These enzymes can function in water,
and require NADPH as a cofactor and molecular oxygen as the
oxidative reactant. While one oxygen atom is introduced
adjacent to the carbonyl group of a ketone substrate, the other
atom is reduced to water as a byproduct.
4,5,12 These green
characteristics have made them intriguing targets for use as
biocatalysts since the prototypical BVMO, cyclohexanone
monooxygenase (CHMO) from Acinetobacter NCIMB 9871
(AcCHMO), was ﬁrst characterized nearly 40 years ago.
10,12
Their frequently exquisite regio- and enantiospeciﬁcities,
combined with their broad substrate proﬁles that include
substituted and bicyclic ketones, make them of particular
interest to the pharmaceutical industry.
4−9 In recent years, a
multitude of homologues of these enzymes have been cloned
and characterized,
4−9 thereby expanding the range of potential
substrates catalyzed by BVMOs.
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recently has any structural data been obtained. The ﬁrst BVMO
to have its structure solved was phenylacetone monooxygenase
(PAMO) from the thermophile Thermobifida fisca.
13 This
structure revealed the overall fold of the enzyme and the
location and conformation of the FAD prosthetic group, which
remains bound throughout the catalytic cycle. Subsequently, we
reported two structures of CHMO from Rhodococcus sp. HI-31
(RmCHMO) in complex with both NADP+ and FAD.
11 This
enzyme is notable for being a close homologue and having a
similar substrate proﬁle to the canonical AcCHMO while being
substantially more stable. The two crystal structures, designated
as CHMOOpen and CHMOClosed, revealed that NADP+ can bind
to the enzyme in two distinct conformations. The sliding of the
NADP+ cofactor deeper into the protein in the CHMOClosed
structure was revealed to be coupled with a rotation of the
NADPH-binding domain so as to create a well-deﬁned
substrate binding pocket. More recently, a series of structures
of PAMO with NADP+ and a weak inhibitor, 2-(N-
morpholino)ethanesulfonic acid (MES), have corroborated
these ﬁndings and provided insight into the conformation of
the reduced ﬂavoenzyme.
14 Intriguingly, the PAMO structures
identiﬁed a funnel-shaped cavity that may provide an alternative
entrance for the substrate to gain access to the active site.
Another recent paper describing NADP+-bound and NADP+-
free crystal structures of 2-oxo-Δ3-4,5,5-trimethylcyclopentenyl
acetyl-CoenzymeA 1,2-monooxygenase (OTEMO), which is
notable for being a dimeric BVMO with a large substrate, also
conﬁrmed the dynamic nature of the BVMO family of
proteins.
15 It should be noted that in addition, a crystal
structure of an atypical BVMO, mithramycin monooxygenase
(MtmOIV) has been obtained.
16 This enzyme has high
sequence and structural similarity to a FAD-dependent
hydroxylase of the glucocorticoid receptor (GR2) subfamily.
This makes it a distant relative of the prototypical BVMOs and
precludes its detailed comparison with CHMO or PAMO.
Structural studies of BVMOs have provided much insight
into these enzymes’ catalytic mechanism; however, they have
also raised questions. Notably, the CHMOClosed structure
reveals that for the majority of CHMO’s substrates, which are
larger than cyclohexanone, there is actually insuﬃcient room in
the active site for the formation of the critical Criegee
intermediate, the adduct of the ﬂavin peroxide and the ketone
substrate that is required for catalysis. Models of the Criegee
intermediate for the cyclohexanone substrate, one of CHMO’s
smallest substrates, suggests that this intermediate can be
achieved in the Closed conformation.
11,17 In contrast, the
Criegee intermediates of larger substrates, such as substituted
or bicyclic ketones on which CHMO readily acts, would result
in severe steric clashes with one or more of NADP+, L146,
F279, and F434 in the Closed conformation. It is clear that in
order for a Criegee intermediate to form, a signiﬁcant
reorganization of the active site is required.
Here, we present the ﬁrst crystal structure of a prototypical
BVMO, represented by RmCHMO, bound to its substrate,
cyclohexanone, as well as NADP+. This structure reveals a
major rotation in the NADP+ cofactor, allowing CHMO to
adopt a catalytically relevant conformation. The rotation
permits the substrate to be positioned above the FAD, thus
revealing a Criegee intermediate-like conformation, a snapshot
of the most important stage of the catalytic mechanism. It also
highlights the role of NADP+ in organizing the active site and
provides a structural explanation for the broad substrate
speciﬁcity of the enzyme, which is necessary for a complete
understanding of the catalytic mechanism.
■ EXPERIMENTAL SECTION
For a description of the subcloning of the chnB1 gene from
Rhodococcus sp. HI-31, the construction of various mutants for NMR
and kinetic studies, and the expression and puriﬁcation of the CHMO
enzyme and its variants, please consult the Supporting Information.
Crystal Structure Determination. Crystals were obtained using
the hanging drop vapor diﬀusion method. Wild-type CHMO was
prepared at 5 mg/mL in 50 mM Tris pH 8.0 and supplemented with a
5× molar excess of FAD and NADP+. In brief, 2 μL of protein solution
was mixed with 2 μL of reservoir solution on an 18 mm siliconized
coverslip (Hampton Research). The reservoir solution consisted of 0.1
M imidazole, pH 8.0, 0.2% TMOS, 20% PEG 3350, and 0.1 M
cyclohexanone. This drop was suspended over a 1 mL reservoir in a
24-well ComboPlate (Greiner Bio-One), and the plate was incubated
at 4 °C. Crystals suitable for diﬀraction studies grew in about one
week.
Data were collected under standard cryogenic conditions on a
Rigaku MicroMax-007HF generator equipped with VariMax HF optics
and a Saturn 944+ CCD detector. The data were processed using the
HKL2000 suite of programs (Table 1).
18 The structure was
subsequently solved using Phaser,
19 employing CHMOOpen (PDB ID
3GWF) as the search model.
11 The model was subjected to multiple
rounds of positional and B-factor reﬁnement using Refmac.
20 Manual
model building was performed regularly during reﬁnement using
Coot.
21 The coordinates and structure factors have been deposited in
the Protein Data Bank as PDB ID 3UCL. Structural ﬁgures were
prepared using PyMOL (Schrödinger LLC).
Saturation Transfer Diﬀerence NMR Spectroscopy. The
buﬀer used for dialysis of the protein was used to dissolve NADP+
at 5 mM. Samples of the buﬀer and NADP+ solution were placed
under vacuum until dry, and then reconstituted in an equal volume of
D2O. A 600 μL sample of 75 μM protein and 1.5 mM NADP+ was
prepared. Samples of the protein without its ligand were also prepared
as a control to conﬁrm that all of the STD signals were derived from
protein−ligand interactions.
Table 1. Data Collection and Reﬁnement Statistics for the
CHMORotated Crystal Structure (PDB ID 3UCL)
Data collection statistics
Space group P212121
a, b, c (Å) 55.5, 67.1, 131.4
Resolution range (Å)
a 30.6−2.4 (2.5−2.4)
Completeness (%)
a 97.9 (92.7)
Redundancy
a 11.2 (8.3)
Rsym
a 8.7 (47.2)
Reﬁnement statistics
Total number of reﬂections (reﬂections in Rfree set) 20,214 (2061)
Rfactor (%) (Work + Free/Free) 19.8/26.4
Number of atoms 4215
Protein 3986
Water 121
Cofactors and Substrate 108
rmsd
Bond length (Å) 0.017
Bond angle (deg) 1.669
Ramachandran plot 505 (100%)
Residues in favored positions 492 (97.4%)
Residues in allowed positions 10 (2.0%)
Residues in disallowed positions 3 (0.6%)
aNumbers in parentheses refer to the highest resolution shell.
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500 MHz spectrometer equipped with a triple resonance HCN cold
probe. A 1D saturation transfer diﬀerence pulse sequence with internal
subtraction via phase cycling was employed to record diﬀerence
spectra.
22 Residual HDO signal was removed using a double pulsed-
ﬁeld gradient spin echo. On-resonance irradiation of the protein was
performed at −0.5 ppm, with oﬀ-resonance irradiation at 36.5 ppm.
Reference spectra were recorded using the same pulse sequence with
saturation pulses applied at 36.5 ppm, and no internal subtraction.
Additional details regarding the NMR experiments are provided in the
Supporting Information.
Enzyme Kinetics. All enzyme assays were performed at 22 °C
using a Cary 50 Bio UV−Visible Spectrophotometer equipped with a
Peltier-thermostatted cell. The enzyme, NADPH, and cyclohexanone
were dissolved at the appropriate concentration in 50 mM sodium
phosphate, pH 8.0. A 500 μL reaction volume was used. To determine
the KM and kcat for NADPH, a series of assays with 100 μM
cyclohexanone (>40× KM(cyclohexanone)) and between 3 μM and 200 μM
of NADPH were used. These experiments were repeated with varying
concentrations of NADP+ to determine the Ki of NADP+.T o
determine the KM and kcat for cyclohexanone, a series of assays with 50
μM NADPH (>8× KM(NADPH)) and between 0.4 μM and 40 μM
cyclohexanone were used. A higher concentration of NADPH could
not be used due to substrate inhibition. In all cases, the NADPH, 10
μL of an appropriate concentration of enzyme, and the substrate were
mixed together to start the reaction. The decrease in absorbance at 340
nm was monitored to determine the initial rate of the oxidation
reaction. The initial rates were plotted against the substrate (NADPH
or cyclohexanone) concentration for each reaction series, and
nonlinear regression was performed using SigmaPlot (Systat Software,
Inc.) to determine the KM and kcat.
A second set of experiments were performed to determine the
uncoupling ratio, deﬁned as the rate of NADPH oxidation in the
presence of cyclohexanone (apparent BV activity) divided by the rate
of NADPH oxidation in the absence of cyclohexanone (NADPH
oxidase activity). Using saturating concentrations of both NADPH
(>6× KM(NADPH)) and cyclohexanone (>40× KM(cyclohexanone)), the
decrease in absorbance at 340 nm was assessed both before and after
the addition of cyclohexanone. Three diﬀerent NADPH concen-
trations were used (40−80 μM), all of which saturated the enzyme,
and the experiments were conducted in quadruplets.
■ RESULTS
Crystal Structure of Substrate-Bound CHMO. The
crystal structure of RmCHMO in complex with FAD,
NADP+, and cyclohexanone was obtained to a resolution of
2.4 Å (Table 1). The polypeptide backbone could be modeled
completely from residues 5−534, with the exception of two
unstructured loop regions from residues 146−149 and 489−
503. The ﬁrst loop region corresponds to a long linker between
the FAD- and NADPH-binding domains, while the second
corresponds to the large loop that is unstructured in the
CHMOOpen structure, but folds in to contact NADP+ in the
CHMOClosed structure. Density consistent with FAD, NADP+,
and cyclohexanone was also visible (Figure 1A). To diﬀer-
entiate it from the CHMOOpen and CHMOClosed structures that
were previously reported, we will refer to this structure as
CHMORotated.
In general, the CHMORotated structure most closely resembles
the CHMOOpen structure (rmsd of 0.56 Å between backbone
atoms present in both CHMOOpen and CHMORotated structures
when the FAD-binding domains are aligned, vs 1.31 Å for
CHMOClosed). When aligning the two structures based on their
FAD-binding domains, the FAD-binding and helical domains
show very little structural divergence. The NADPH-binding
domain shows a slight rotation, though this is signiﬁcantly less
pronounced than the substantial domain movements seen
when comparing the CHMOOpen and CHMOClosed structures.
This rotation allows for a subtle shift in the position of the
adenine portion of NADP+, which may in turn trigger the
rotation of its nicotinamide moiety.
Rotation of the NADP+ Cofactor. One of the most
signiﬁcant features in the crystal structure is the large rotation
of the nicotinamide phosphoribose of NADP+ when compared
to CHMOOpen and CHMOClosed (Figure 1B). It is for this
reason that we refer to it as the CHMORotated structure. This
rotation serves to displace the nicotinamide head away from its
position above the isoalloxazine ring system of FAD and into
the large, primarily hydrophobic cavity that is seen in the
CHMOOpen structure. This movement has two notable eﬀects.
By rotating away from the FAD ring system, space for the
substrate to enter into the catalytic position is created. Second,
the nicotinamide head serves to partially block the active site
region from the bulk solvent, which prevents the substrate from
diﬀusing back into solution while the protein is in the Rotated
conformation (Figure 2). It is notable that the nicotinamide
moiety forms relatively few strong interactions in this
conformation.
The new conformation of NADP+ allows the formation of
intramolecular hydrogen bonds between the 3′ hydroxyl of the
nicotinamide ribose and both the nicotinamide and the adenine
phosphates. This intramolecular interaction stabilizes this
conformation of the NADP+ and may be a driving force in
the adoption of this conformation.
Figure 1. View of the active site in the CHMORotated (green) structure. The positions of FAD, NADP+, and cyclohexanone are shown. (A) The Fo −
Fc electron density map contoured at 3.0σ around NADP+ and cyclohexanone is shown as a blue mesh. The map was calculated with the ligands
omitted from the model. (B) Stereo view with the position of NADP+ in CHMOClosed (blue) overlaid on the CHMORotated crystal structure. Key
residues R329, L145, and F507 and water molecule 601 are also shown.
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Electron density corresponding in size and shape to what is
expected for cyclohexanone was observed above the isoallox-
azine ring system of FAD; therefore, we proceeded to model
the substrate at this position (Figure 1A). The carbonyl oxygen
of cyclohexanone appears to be oriented through interactions
with D59 and R329. Both of these residues have been
previously implicated in controlling the position of
NADP+,
11,13,23 as well as in the positioning of a weak inhibitor
of PAMO.
14 A nearby water molecule (H2O 601) also forms a
weak hydrogen bond with the carbonyl oxygen, linking it to
Q192, the backbone atoms of residues L57 and D59, and a
larger solvent network.
It is known that the formation of the Criegee intermediate,
the key catalytic step in the BVMO reaction mechanism,
involves a nucleophilic attack on the carbonyl carbon of
cyclohexanone by the peroxyanion intermediate, in which the
peroxyanion is covalently linked to the C4X carbon of FAD.
The distance between C4X and the carbonyl carbon is 3.9 Å in
this crystal structure. With the FAD-linked oxygen of the
peroxide group expected to occupy an axial position relative to
the FAD ring system, if the anionic oxygen were to point
toward cyclohexanone, the position occupied by cyclohexanone
in this structure would correspond approximately to the
expected position for the nucleophilic attack and formation of
the Criegee intermediate. A model of the Criegee intermediate
that imposes antiperiplanar geometry required for migration of
the carbon to form the lactone
24 shows that cyclohexanone
nearly coincides with its position in the model of the
intermediate (Figure 3). A shift of ∼0.5 Å is required to
superimpose the carbonyl carbon of the cyclohexanone
molecule and the intermediate, after which a ∼30° rotation is
suﬃcient to make the molecules overlap.
Structure−Function Studies Probing the Rotated
Conformation. To probe the relevance of the observed
Rotated conformation for catalysis, we designed three mutants
t h a tw e r ep r e d i c t e dt os p e c i ﬁcally perturb nicotinamide
cofactor binding in the Rotated conformation, while having
no impact on the cofactor in either the Open or Closed
conformations. The three mutants, L145N, L145D, and F507Y,
are anticipated to stabilize the catalytic conformation by
forming a polar contact with the carboxamide group of
NADP+ in the Rotated conformation. In contrast, in the
CHMOOpen and CHMOClosed structures, these residues should
not interact directly with the cofactor, with the nearest distance
in either structure being more than 5 Å. Given that many of the
residues implicated in NADP+-binding in the CHMORotated
structure are also involved in substrate speciﬁcity, the rational
design of destabilizing mutations speciﬁc for the Rotated
conformation was not feasible.
To assess the degree of perturbation in the NADP+ binding
mode caused by these mutations, transferred nuclear Over-
hauser eﬀect (Tr-NOE) and saturation transfer diﬀerence
(STD) NMR experiments were performed. No major diﬀer-
ences were observed between the Tr-NOESY spectra of
NADP+ in the presence of wild-type CHMO or any of the
three mutants, as only some slight changes of NOE intensities
and appearance and disappearance of the weakest NOEs were
observed. This suggests that the overall set of conformations
available to NADP+ in the mutants is not signiﬁcantly
perturbed. In the STD experiments, the aim was to assess if
there was a diﬀerence in the relative enhancement of the STD
eﬀect of the pyridine protons as compared to the adenine
protons when the mutants were compared to the wild-type
protein. The diﬀerences observed were subtle, and preclude a
discussion of the eﬀects of the mutations on any individual
proton; however, when the STD eﬀect of the four protons on
the pyridine ring (N2, N4, N5, and N6) was compared to the
STD eﬀect for the two adenine ring protons (A2 and A8, where
A2 is used as the reference for the STD eﬀect), a trend could be
observed (Supporting Information Figure S1). The interactions
between the protein and the pyridine protons appeared closer
than the protein−adenine proton interactions in the mutants as
compared to the wild-type CHMO. This is consistent with a
minor selective stabilization of the nicotinamide moiety binding
mode in the Rotated conformation.
While the structural impact of the mutants was subtle, as
assessed by NMR methods, t h ei m p a c to nt h ek i n e t i c
properties of CHMO was substantial (Figure 4, see Supporting
Information Table S1 for complete kinetic data). In comparing
the KM values for NADPH, the wild-type had the highest KM,
suggesting that all three mutants bind the cofactor more
strongly during catalysis. It should be noted that all the KM
values were within an order of magnitude of each other.
Furthermore, in terms of kcat, all three mutants had substantially
lower rates than the wild-type, with the kcat dropping by at least
a factor of 6 and by as much as a factor of 100. This eﬀect was
seen for the kcat of both NADPH and cyclohexanone. This
Figure 2. NADP+ blocks cyclohexanone from diﬀusing into the bulk
solvent in the Rotated conformation. The protein surface is shown in
gray. NADP+ is shown in stick representation and its surface is
outlined in blue. Cyclohexanone is shown using green space-ﬁlling
representation.
Figure 3. The CHMORotated crystal structure (green) is shown
superimposed on a model of the Criegee intermediate (cyan). The
model was produced using molecular dynamics followed by energy
minimization in Chem3D, while enforcing the antiperiplanar geometry
required for migration of the carbon.
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slightly improved, the mutations appear to have signiﬁcantly
slowed the reaction rate. The Ki for NADP+ as a competitive
inhibitor of CHMO is discussed in the Supporting Information,
and is largely consistent with the observed trend for NADP+
binding aﬃnities in the mutants.
The uncoupling ratio is an indicator of the eﬃciency of the
complete Baeyer−Villiger reaction (BV activity) relative to the
eﬃciency at which NADPH would be used in the absence of
cyclohexanone (NADPH oxidase activity). The wild-type
enzyme exhibits the largest uncoupling ratio of 114. For the
three mutants, this ratio is signiﬁcantly reduced, ranging from 4
to 20. To assess how much of this change is caused by the
decrease in BV activity and how much is due to changes in the
amount of unproductive NADPH oxidase activity, the
normalized uncoupling ratio was compared to the normalized
kcat/KM(NADPH) and kcat/KM(cyclohexanone) values, using the wild-
type values as 100% (Supporting Information Figure S2). Note
that both kcat/KM values were determined using the apparent
BV activity (which includes unproductive NADPH oxidase
activity in the presence of cyclohexanone), not the uncoupled
reaction (NADPH oxidase activity). For all three mutants, the
uncoupling ratio was signiﬁcantly greater than would be
predicted by the normalized kcat/KM(cyclohexanone), and moder-
ately smaller than predicted by the normalized kcat/KM(NADPH).
■ DISCUSSION
A Third NADP+ Conformation. Previous structural studies
of BVMOs have raised a critical question: how is the enzyme
capable of eﬀecting catalysis with a structure that has its active
site blocked by the NADP+ cofactor? The NADP+ has been
shown to be bound throughout the catalytic cycle,
23,25,26
presumably to stabilize the peroxyanion intermediate, preclud-
ing the possibility of dissociation of NADP+ prior to substrate
binding. At the same time, much of the space required for the
substrate to form the expected Criegee intermediate is blocked
by NADP+ and other key residues. The rotation of the
nicotinamide away from the FAD provides an explanation for
how the substrate can enter the space close to the peroxyanion
intermediate while NADP+ remains bound. In this conforma-
tion, the substrate sits in a putative catalytic position that is
large enough to accommodate CHMO’s larger substrates.
While the structure resembles the Open conformation, the
rotation of the NADP+ nicotinamide blocks oﬀ much of the
space that is available in the CHMOOpen structure (Figure 2),
and a shifting of the key residue, R329, narrows the channel
further to prevent the substrate from diﬀusing away from the
peroxyanion intermediate. In this way, the substrate is “locked”
into the active site pocket in the Rotated conformation. We
propose that in order to avoid the rapid collapse of the
peroxyanion intermediate, the substrate is bound in the
previously reported Open and Closed conformations. The
relatively weak interactions between the nicotinamide and the
protein in the Rotated conformation would disfavor this
conformation unless the substrate was able to replace some of
the lost interactions. In other words, the enzyme would be
locked in a conformation that stabilizes the peroxyanion
intermediate until the substrate is present in the substrate
binding site observed in the CHMOClosed structure. At that
point, the enzyme can switch into the Rotated conformation,
allowing catalysis to occur.
The NMR and kinetic data for wild-type and CHMO
mutants are in agreement with this proposal. The three mutants
were designed such that the altered residues would form
favorable interactions speciﬁcally with the observed Rotated
conformation of the nicotinamide cofactor while having no
interactions with this cofactor in either the Open or Closed
conformations of the enzyme. The NMR data supports that the
design of the mutants was successful as the STD data for the
mutants show that the pyridine moiety is bound with higher
aﬃnity relative to the adenine moiety. This is consistent with
the stabilization of a minor conformational state for the
pyridine moiety akin to that observed in the CHMORotated
structure. Kinetic studies reveal that the mutants display a
moderate increase in the aﬃnity of NADP+, as seen by the
decrease in KM. This observation strongly suggests that the
Rotated conformation is an enzyme state that must occur
sometime during the reaction cycle of CHMO. Moreover, the
reaction rate is signiﬁcantly decreased (6- to 100-fold). This
change in kcat for the mutants implies that the enzyme is
spending longer than usual in one or perhaps more catalytically
critical steps during the reaction cycle. Finally, the uncoupling
ratio data provide insight into which speciﬁc step in the
reaction mechanism might be delayed. For reasons discussed in
the Supporting Information, the uncoupling data are consistent
with the interpretation that the mutants are less eﬃcient in
stabilizing the peroxyanion intermediate, compared to the wild-
type enzyme. This is in agreement with the adoption of the
Rotated conformation prior to the binding of the ketone
substrate in the mutants, leading to the destabilization of the
peroxyanion intermediate and uncoupling of NADPH con-
sumption from BV activity. Given that this is the case, it would
be expected that the Rotated conformation most likely occurs
when the ketone substrate is present, as we propose based on
our structural data.
The Rotated structure highlights the need of this enzyme to
adopt several arrangements of the substrates and cofactors in
order to catalyze the elaborate chemical mechanism. This is a
phenomenon seen in other ﬂavoenzymes, including the well-
studied para-hydroxybenzoate hydroxylase
27−31 and phenol
hydroxylase,
32,33 the former being one of the ﬁrst ﬂavoenzymes
to have its structure solved. Like the BVMOs, these
hydroxylases face the problem of needing to bring the substrate
in close proximity to a ﬂavin peroxide intermediate that is
inherently unstable in protic solvents.
34 The details and order
of substrate and cofactor binding and release are diﬀerent, as
are the solutions employed to overcome this problem. In spite
of this, both the hydroxylases and the BVMOs employ changes
in the relative arrangements of the substrates and cofactors at
diﬀerent stages of their catalytic mechanisms to protect the
peroxide while permitting the reaction of the substrate to
Figure 4. The KM and kcat of NADPH for the wild-type and the three
mutants are shown. Error bars correspond to the standard error as
determined by nonlinear regression.
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34 The hydroxylases employ three conformations,
involving a large rotation of the FAD cofactor, to move from
a substrate binding position
31 to a ﬂavin reduction position
27,28
and ﬁnally to a substrate hydroxylation position.
27,29,30 With
CHMO, it is the NADP+ that moves from a ﬂavin reduction
position to a substrate binding position and ﬁnally to the
Criegee position. In both cases, the peroxyanion intermediate is
maintained in a protected environment until the moment that
the reaction with the substrate can occur.
34
This does not mark the ﬁrst time a ﬂavin-dependent
monooxygenase (FMO) has been observed to have NADP+
present in a rotated conformation. In a recent study, two crystal
structures of an FMO from Methylophaga sp. strain SK1
(mFMO) were obtained with a similar conformation of NADP+
(Supporting Information Figure S3).
35 These structures were
obtained using a mutant enzyme or a NADP+ analogue. As
mFMO has substantial structural diﬀerences as compared to
CHMO, the minor diﬀerences in the conformation are to be
expected. As mFMO has a much more open structure than
CHMO, there is no need for the enzyme to adopt an alternate
conformation to allow catalysis to occur. As such, this
conformation is considered to be a product of the high
promiscuity of mFMO.
35 With CHMO, we can see this as being
a critical conformation during the catalytic cycle.
The Catalytic Position of Cyclohexanone. The
CHMORotated structure unveils the position of CHMO
immediately prior to the reaction with the peroxyanion
intermediate to form the Criegee intermediate. Indeed, we
see the substrate close to the ideal geometry for catalysis to
occur. Assuming that the peroxyanion intermediate were to
form prior to adoption of this conformation, a slight shift in the
position of the substrate would result in the necessary geometry
for nucleophilic attack on the carbonyl carbon of the ketone. In
addition, a fairly minor rotation will result in the antiperiplanar
geometry required for the migrating group to form the
necessary bond with the peroxide oxygen.
Intriguingly, many of the residues previously implicated in
determining the substrate speciﬁcity of CHMO and other
BVMOs,
36−43 which generally line the pocket observed in the
CHMOClosed structure, are not in the vicinity of the substrate in
the CHMORotated structure. This suggests that the Rotated
conformation is not the most important conformation for
determining substrate speciﬁcity, regiospeciﬁcity, and enantio-
speciﬁcity of the enzyme. Rather, the putative substrate binding
pocket observed in the CHMOClosed structure is critical in
determining the substrate proﬁle of the enzyme. We can
speculate that the key residue R329 may play a role in guiding
the substrate from the Closed conformation pocket to the
Rotated conformation position while maintaining the chemo-,
regio-, and enantiospeciﬁcity dictated by the CHMOClosed
structure.
Given the apparent necessity for a substrate-bound form in
the Closed conformation, it appears likely that CHMO employs
a series of conformational changes to gradually move the
substrate from the solvent into the position observed in the
CHMORotated structure. In contrast to this, a recent study has
reported multiple structures of PAMO with bound NADP+,
14
all of which were obtained in a conformation similar to the
CHMOClosed structure, and some of which also had bound
MES, a weak inhibitor of PAMO. The MES inhibitor was
observed in a funnel-shaped cavity leading to the catalytic site,
suggesting that this is a potential route for the substrate to enter
the active site. This arrangement has been previously observed
in other ﬂavoproteins, like ornithine hydroxylase.
44 In CHMO,
Figure 5. Schematic of the proposed mechanism for CHMO. The schematics are labeled A to J to correspond to the states referred to in the text.
Both the schematics and the chemical mechanism shown in the center are colored using the same scheme. The FAD is denoted by three fused
hexagons. The reduced NADPH is shown in blue, with the adenine portion as a rectangle, the nicotinamide as a hexagon, and the phosphate
backbone as a thick wavy line. The oxidized NADP+ is shown in red. The substrate is shown in green, the lactone in orange, and the Criegee
intermediate in brown. The peroxyanion moiety is shown in blue attached to the FAD.
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PAMO (residues 278−279, CHMO numbering) (Supporting
Information Figure S4), precluding its use for substrate binding
in RmCHMO. On the basis of sequence alignments, this
dipeptide insert is conserved in almost all CHMOs, including
AcCHMO, as well as a number of other closely related BVMOs.
The funnel is also blocked in the structures of OTEMO.
15 It
might be that BVMOs like CHMO and OTEMO use diﬀerent
mechanisms for substrate binding as compared to PAMO: the
former by adopting a series of conformations that progressively
move the substrate toward the catalytic position, and the latter
via a tunnel that allows for a “back door” access. The possibility
that CHMO and PAMO employ slightly diﬀerent mechanisms
is not new; when the detailed kinetic mechanism for PAMO
was elucidated,
23 it was seen that a spectral change associated
with a conformational change during NADP+ release in
CHMO
26 was not observed. It is also possible that the more
limited substrate proﬁle of PAMO as compared to other
BVMOs
37,40,42,45 is related to this diﬀering substrate binding
mechanisms.
A Structural Mechanism for BVMO Catalysis. The
CHMORotated structure allows us to propose a mechanism for
BVMO catalysis from a structural perspective that is consistent
with the previously elucidated kinetic mechanism of
BVMOs.
23,25,26 The structural states referred to here will
correspond to the states shown in Figure 5. The catalytic
mechanism begins in the NADP(H)- and substrate-free form
(state A). Following binding of NADPH (state B) and reduction
of FAD in an Open-like conformation, the NADP+, R329, and
D59 will occupy positions that stabilize the reduced ﬂavin.
Molecular oxygen will react with the reduced ﬂavin, forming the
peroxyanion intermediate (state C), which is also stabilized by
the same residues. This would also likely take place in a state
resembling the Open conformation. The substrate will then
bind weakly in the diﬀuse binding pocket observed in the
CHMOOpen structure (state D). This will trigger the
reorganization of the large, unstructured loop, permitting the
enzyme to adopt a tight-binding, CHMOClosed-like structure
(state E). It is this structure that will determine whether a
substrate will be accepted by the enzyme, as well as what the
regio- and enantiospeciﬁcity will be. From there, the enzyme
will switch into the peroxyanion intermediate version of the
Rotated conformation. This involves the rotation of NADP+,
the migration of the substrate into the catalytic position, and
the shifting of R329 (state F). We speculate that R329 plays the
role of a chaperone guiding the substrate into the catalytic
position without allowing it to reorient. This would allow the
preservation of the stereochemical requirements imposed in the
Closed conformation. At the same time, NADP+ obstructs the
exit pathway, preventing the substrate from diﬀusing away from
the reaction site. Formation of the Criegee intermediate will
occur (state G), followed by the formation of the lactone
product. Once the product is formed, the enzyme will reverse
its steps. The R329 will reposition the product, allowing the
NADP+ to return to its position above the ﬂavin rings. This
may occur in two stages, with the lactone returning to the tight-
binding pocket in the CHMOClosed structure (state H) before
switching to the Open conformation (state I), or it may switch
to the Open conformation directly (state I). Either way, the
Open conformation causes the product to be bound again in
the loose-binding mode. The product can then be released to
the solvent (state J), followed by the release of the oxidized
NADP+ cofactor, and the return of the enzyme to the initial
state (state A).
The schematic shown in Figure 5 emphasizes the fact that
the protein accommodates a variety of ligand positions, of
which three have been observed directly with crystal structures.
In spite of this, it appears to do so using only two major global
protein conformations: Open-like conformations and Closed-
like conformations.
■ CONCLUSION
Up to now, there has been a considerable gap in our
understanding of the structural mechanism of the BVMOs.
The lack of a crystal structure with the substrate bound to the
enzyme has prevented a structural description of the enzyme
state allowing for the formation of the Criegee intermediate.
The structure presented here shows for the ﬁrst time a
catalytically competent structure of a BVMO. Indeed, it places
the ketone substrate in an ideal position for the formation of
the Criegee intermediate. At the same time, it provides the
necessary space and ﬂexibility for the accommodation of a wide
range of substrates of various sizes. Finally, it provides a
solution to the problem of how the substrate can reach the
active site while the NADP+ cofactor remains bound that is
consistent with the established kinetic mechanism. This ﬁlls a
critical gap in understanding of the catalytic mechanism of the
BVMOs, and has allowed us to propose a structural description
of the mechanism of this family of enzymes.
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